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Abstract
Dry powder inhalers (DPIs), used as a means for pulmonary drug delivery, typically
contains a combination of an Active Pharmaceutical Ingredient (API) and significantly larger
carrier particles. The micro-sized drug particles - which have a strong propensity to aggregate and
a poor aerosolization performance - are mixed with significantly large carrier particles that are
unable to penetrate the mouth-throat region to deagglomerate and entrain the smaller API particles
in the inhaled airflow. The performance of a DPI, therefore, depends on entrainment the carrierAPI combination particles and the time and thoroughness of the deagglomeration of the individual
API particles from the carrier particles. Since DPI particle transport is significantly affected by
particle-particle interactions, very heterogeneous particles sizes and shapes, various forces
including electrostatic and Van der Waals forces, they present significant challenges to
Computational Fluid Dynamics (CFD) modelers to model regional lung deposition from a DPI. In
the present work, we develop a novel high fidelity CFD Discrete Element Modeling (CFD-DEM)
method and sensitivity analysis for predicting the transport and deposition for DPI carrier and API
particles. The proposed development will leverage exascale capable CFD-DEM and sensitivity
analysis capabilities from Department of Energy (DOE) laboratories: Multiphase Flow Interface
Flow Exchange (MFiX) and DAKOTA UQ software, and Trilinos portable scalable linear algebra
libraries. We validate the models with available data from the literature for DPI and conduct a
sensitivity analysis of various formulation properties and their effects on particle size distribution
with DAKOTA. Ideal particle size can be determined based on residence time for better DPI
performances and respiratory deposition. Current analysis shows that drug particles of 1-3.66 µm
show a higher drug dispersion and better aerosolization behavior with carrier particles between
51-63 µm on basis of residence time.
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Chapter 1: Introduction
1.1

OVERVIEW
Asthma is one of the most chronic distressing diseases in the United States. It is a

rapidly escalating pulmonary disease that causes breathlessness, chest tightness, coughing and
forced breathing [1]. Dry powder inhalers (DPI) directly deliver the drug to the target areas and
provide more drug choices especially for those poorly absorbed orally [1–7]. These methods result
in rapid onset of activity with small doses compared to injection and oral administration. In
addition, DPIs do not contain chlorofluorocarbons (CFC). On the other hand, metered-dose
inhalers contain CFC and damages the ozone layer. In general, drug particles of size less than 5
µm are used for the application in DPIs. In inhalation process, the particles are mixed with larger
carrier particles as they are very cohesive and have poor flowability. The agglomerates disintegrate
into small fractions or the drug particles detach from the carrier particle for the delivery of drugs
to the lungs. Therefore, the cohesive/adhesive forces have to be sufficiently strong to aggregate
and transport the particles, but weak enough to be overcome by the removal forces generated
during the de-agglomeration process [8–10]. In addition, the adjustment of attachment between
medicate particles and bond amongst bearer and medication particles was likewise found to
influence the DPI performance [11, 12]. To better comprehend the systems of the agglomeration
and deagglomeration forms, numerous examinations have been directed to investigate the impacts
of particle shape [13], particle size [14–17], particle concentration [18], particle surface roughness
[19], density and porosity [20], surface energy [21], material properties [22], storage conditions
[23], crystal form [24], electrostatic charge [25], flowability [26] and the type of ternary additives
[27] on the performance of dry powder inhalers. Those customary and progressed test approaches
gave a point by point comprehension of the overseeing factors in DPIs. Notwithstanding, it is to a
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great degree hard to recognize the impact of a solitary factor on DPI execution because of the
many-sided quality of DPI systems [28]. The instruments of the agglomeration and
deagglomeration forms are still inadequately comprehended [29].
Numerical simulations are widely in investigation of fluid flow and particle behavior. In
Computational fluid dynamics (CFD), Navier-Stokes equations are discretized with a numerical
method to simulate both laminar and turbulent flows [30–33]. Flow patterns as well as inhaler
optimization are possible with CFD as well [34–36]. On the other hand, the discrete element
methods (DEM) [37–39] provide detailed information of a particulate system at the single particle
level. The particle trajectory is easy to obtain with this method unlike conventional experiments.
It gives the connection between the macroscopic and microscopic properties of particulate matter,
which is crucial in investigation of dry powder inhalers [40]. In addition, coupling DEM with CFD
enables the approach to model the interactions between the fluid and particles [41, 42]. However,
recent improvements to DEM can accommodate the electrification phenomenon [43] and the
particles with irregular shapes [44].

1.2

OBJECTIVE
In the present work, numerical code Multiphase Flow with Interphase eXchanges (MFiX)

is used for simulations. This software can model chemical reactions and heat transfer in dense and
dilute gas–solid flows. Cartesian coordinate systems are used to solve the transport equations. The
purpose of this present work is to show the range of validity for using simulations based on a 2D
Cartesian coordinate system to assess a rectangular fluidized bed with different parameter. The
simulations will be conducted for different inlet gas velocities with different particle diameter,
which correspond to the bubbling and slugging regimes of fluidized beds. After these studies, we
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will try to develop a novel high fidelity discrete element (CFD-DEM) method and sensitivity
analysis is carried out for predicting the transport and deposition as well as the agglomeration and
deagglomeration for DPI carrier and API particles. The CFD-DEM algorithm models
agglomeration and deagglomeration forces with MFiX. We will validate the models with available
data from the literature for DPI and conduct a sensitivity analysis of various formulation properties
and their effects on particle size distribution with DAKOTA. Based on the available data from the
literature for DPI, carrier and drug particle size has been chosen and MFiX-DEM analysis will be
done on these ranges to obtain better DPI performances. The objective of this study is to obtain
the DPI performance over large range of particle sizes on basis of particle residence time using
MFiX-DEM method. As device performances also depends on the fluid flow inside inhaler
domain, Computational Fluid Dynamics (CFD) analysis will be done to visualize the flow inside
DPI.

1.3:

PROJECT OUTLINE
This dissertation contains a total of 6 chapters:



Chapter 1 gives a brief idea of the project and focus on the following chapters. This chapter
discusses the use and benefits of dry powder inhaler and also explains the project objective.



Chapter 2 in this thesis describes the past literature that contributes to the concepts used in
this thesis. Different types of inhaler and a detailed background on DPI is discussed on that
chapter.



Chapter 3 focuses on the problem statement, specifically focused in building a framework
that can solve the problem directly related to these applications.
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Chapter 3.2 schematically explains the framework of integrating MFiX-DAKOTATrilinos softwares in order scale the fluidized bed problem and for predicting the transport
and deposition of DPI particles. This thesis discusses the development of an exascale
capable framework that handles the computational fluid dynamics and uncertainty
quantification methodologies involved for predicting the transport and deposition of DPI
particles.



Chapter 4 discusses the associated softwares like Multiphase Flow Interface Flow
Exchange (MFiX) and DAKOTA UQ software, and Trilinos portable scalable linear
algebra libraries used in developing the framework of Chapter 3. This chapter covers the
motivation and detailed capabilities of these softwares and their implementation in
computational modeling.



Chapter 5 shows the results obtained from solving the fluidized bed problems with different
parameters and different sizes of computational domain with DPI and analyzes the
performance of DPIs on MFiX-DEM simulations.



Chapter 6 summarizes the work completed and concludes the current thesis outcomes
based on the results obtained on previous chapter. The scope for future work is also
discussed for further improvements of this research possibilities.
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Chapter 2: Background & Literature Review

2.1: INTRODUCTION:
The development of inhalation device is very important to deliver adequate quantity of
inhaled drug to lungs. Oral inhalation drug delivery needs to aerosolize the drug compound in
delivery device. To aerosolize drug compounds, three major approaches have been used; liquid
drugs can be volatilized with compressed air or oxygen mixtures that consequently are breathed
in, liquid solutions or solid powders can be pneumatically fluidized into a dispersed aerosol stream
that is inhaled, or solid powders can be dispersed into a stream of passively inhaled air [44, 45].
The design of the device should have an environment where the drug can maintain its
physicochemical stability and produce reproducible drug dosing [6]. Different types of inhaler
devices are commercially used for asthma and chronic obstructive pulmonary diseases (COPD).
In this chapter, we will discuss about different types of inhaler and previous studies on DPI that
have dealt in problems of DPI and DPI particle transport over fluidized bed applications and how
it is implementing in high performance computing.

2.2: TYPES OF INHALER:
For asthma and COPD medicines, different types of inhaler devices are used: metered-dose
inhalers (MDIs), dry powder inhalers (DPIs) and mist inhalers. The most common and older form
of inhalers are called metered dose inhalers (MDIs). The basic principle of MDI is by pressing
down on the inhaler top, which release a liquid amount of the medicine into the lungs, when
inhalation occurs at the same time. These devices are made of three standard components- a metal
canister, plastic actuator, and a metering valve. In MDIs, medication or capsule is usually stored
in solution in a pressurized canister which contains a propellant [46]. The propellants should be
5

nontoxic, nonflammable, and compatible with drugs formulated either as solutions or suspensions
[47]. The metal canister is attached to a plastic, hand-operated actuator. This type of inhaler
discharges a fixed dose of medication in aerosol form while activated. The exact method of using
an MDI is to first fully exhale then place the mouth-piece of the device into the mouth, and
afterward inhale at a moderate rate which depends on patient’s condition and dosage, and at last
press down the canister to release the medicine. Some inhalers are made in such a way that may
act later and others are made to act instantly in case of an asthma attack. The schematic of a metered
dose inhaler (MDI) are shown in Figure 2.1.

Figure 2.1: Schematic and working principle of metered dose inhalers (MDIs) 5
Due to the change of asthma inhalers profile and needs, there is another type of inhalers
where propellant is being used in the form of a dry powder is called dry powder inhaler or DPI.
Like a metered dose inhaler, DPI is a handheld device that delivers a measured dose of asthma
medicine accurately in the form of dry powder into the lungs. The DPIs design has been advanced
in such a way that the device should generate adequate turbulence and particle–particle collisions
to separate the drug particles from carrier surface of an interactive mixtures or deagglomerate
6

particles from large agglomerates of drugs only [48]. To prepare the dose for fluidization with
tangential flow of air at the time of patient inspiration, most of the DPI devices are primed by
pressing (Rotahaler®), sliding (Spinhaler®), rotating (Twisthaler®) or piercing (Handihaler®)
[49]. Then the fluidized powder is passed through a screen to deagglomerate particles for deep
lung delivery. The main difference between a DPI and a MDI is that in DPI, powder is kept in
small amounts in different chambers instead of “press/squirt/inhale” action like MDI. In a DPI, the
medication comes in a dry powder form. A small capsule, disk, or compartment inside the inhaler
device is used to hold the medication [50, 51]. The schematic of a dry powder inhaler (DPI) is
shown in Figure 2.2.

Figure 2.2: Schematic of dry powder inhaler (DPI) 9
This device consists of a metering system, an actuator and the dry formulation. The bulk
chamber is covered by an over-cap and holds the formulation. A dust-cap is used to cover the
mouth-piece for preventing contamination. The metering valve extracts the powder from the
chamber and moves it forward to the mouth-piece for inhalation. A dry powder inhaler (DPI)
delivers the drug in the form of particles confined in a capsule or blister which needs to be
7

punctured before use. The patient requires a negative inhalation to deliver the medication as
‘respirable’ aerosol [52]. The working principle of a DPI is pretty simple, which is discussed
below:


A strong inhalation may require several seconds.

Figure 2.3: DPI operation from actuation to lung delivery51


Patient will have to place the inhaler's mouthpiece in his mouth and close his lips
tightly around the mouthpiece.



After rotating the inhaler chamber or clicking a piece on the inhaler, patient is
required to inhale quickly and deeply through his mouth for few seconds which
releases the medicine directly to the lungs.



After the medicine is inhaled, breath should be held for a few more seconds to let
the medicine settle in lungs. Then the patient can breathe out slowly through pursed
lips.
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It is recommended to hold the inhaler away from mouth while you breathe out. It
can blow the powder medicine out of the inhaler and the moisture from breath can
cause the dry powder to clump together and clog the inhaler.



As this type of inhaler does not contain a propellant, so it needs a sufficient
inspiratory flow rate for drug delivery. Because of this requirement of an
inspiratory flow, this type of devices (DPIs) are not suitable for the treatment of
acute asthma attacks [53].

2.3: DPI BACKGROUND:
The pressurized metered-dose inhaler (pMDI) was invented by Irvine Porush and George
Maison in 1955 and became the most commonly used device to deliver inhaled asthma drugs on
that time. Pulmonary drug delivery via pMDIs, DPIs or nebulizers are the preferred treatment
methods for asthma patients. The pressurized metered-dose inhalers (pMDIs) were the most
commonly used inhaler devices for asthma and COPD patients for many years. But after
implementing the Montreal Protocol in 1987 for limited use of CFCs in MDIs, DPIs became the
most preferable devices [54]. To overcome the problems associated with nebulizers and MDIs, dry
powder inhalers were developed to provide an alternative way of delivering medication to the
lungs. With the advancement of science and technology, pulmonary delivery of drugs has become
the route of choice after the introduction of the DPI in 1967. After the development in 1960s and
1970s, the original DPI devices used patient's inspiratory flow to disperse the aerosol from capsule
unit doses and deliver it to the airways [55].
There are a significant number of commercial dry powder inhalers available, which vary
in dispersion efficiency because of their design characteristics. There has been lots of development
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done on DPIs after that. There are lots of commercially available DPI devices exist in market based
on their dosage capability, breathe activated and power driven properties. Based on the design,
DPI devices are categorized into three wide groups, i.e., the first generation DPIs, the second
generation DPIs and the third generation DPIs [52]. The first-generation DPIs were small, breath
activated single unit capsule-based passive devices like Spinhaler® and Rotahaler®. With better
technology, the second-generation DPIs depend on more sophisticated devices, such as reservoirs
and micronized powders (e.g., Turbohaler) [56]. The third and newer generation DPIs are active,
power-assisted inexpensive devices that are highly dispersible and can incorporate with batterydriven impellers and vibrating piezo-electric crystals (e. g. MicroDose ® ; MicroDose Therapeutx,
Monmouth Junction, N.J., USA) [57].

Figure 2.4: Different types of dry powder inhalers (DPIs) 51
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Numerous studies have been done on successful delivery of drugs into the deep lungs
which mainly depends on the amalgamation between powder formulations and the device
performance [58]. Voss and Finlay developed a powder de-agglomeration device to investigate the
effects of turbulence and mechanical impact on dry powder de-aggregation which showed that the
range of de-aggregation increased as the level of turbulence was increased [59]. In order to explore
in which rate API particles are detached from carrier particles in an air classifier, a study found
that the rate increased with increasing flow rate and dispersion time [60]. Another research showed
an aerodynamic dispersion of loose aggregates in a uniform fluid flow using DEM–CFD and found
a threshold velocity above which dispersion occurred rapidly and approximated equilibrium
asymptotically [61]. All of these works showed the overall DPIs behavior and the mechanical
analysis of dispersion behavior of loose agglomerate. Lots of studies have been done on the particle
size of inhalation aerosols. Many studies showed that the optimal aerodynamic diameter for DPIs
are between 1 and 5 mm when they are operated at inspiratory peak flow rates between 30 and 150
L/min [62]. The wider size distribution in DPIs may benefit the distribution throughout the lungs.
However, other researches indicated that use of monodisperse particles or narrow size distributions
with controlled inspiratory flow rates and inhaled volumes, shows better aiming of particular
deposition sites, as well as reducing adverse side effects [60].

2.4: SUMMARY:
The inhalation of asthma medicine in powder form may reach instantly the lungs without
producing any type of coughing. The use of very fine powdered medicine in miniscule doses can
be very effective in DPI. Though DPI is much more advanced than MDI, it has also some
limitations. DPI may not be suitable for very young children and people with extremely weak
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breath. Since DPI particle transport is significantly affected by particle-particle interactions, very
heterogeneous particles sizes and shapes, various forces including electrostatic and Van der Waals
forces, they present significant challenges to CFD modelers to model regional lung deposition
from a DPI. Though lots of investigations have been done in DPI and DPI particle transport, but
carrier-based DPIs at the micro-mechanical level investigation was hardly reported.
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Chapter 3: Problem Definition

3.1: INTRODUCTION:
This thesis discusses the development of an exascale capable framework that handles the
computational fluid dynamics and uncertainty quantification methodologies involved for
predicting the transport and deposition of DPI particles. For handling such a large scale scientific
applications via enhanced communication, robust memory management and integration of the
CFD and UQ interface, the framework is required. The objective of this project is to show the
range of validity for using simulations based on a 2D Cartesian coordinate system to assess a
rectangular fluidized bed with different parameter. And the next step will be to develop a novel
high fidelity discrete element (CFD-DEM) method and sensitivity analysis for predicting the
transport and deposition as well as the agglomeration and deagglomeration for DPI particles. This
chapter focuses on the problem statement, specifically addressed in building a framework that can
solve the problem directly related to these applications.

3.2: PROBLEM DEFINITION:
Figure 3.1 illustrates the schematic of a framework that integrating the CFD and DEM
interface. This project will integrate the CFD and DEM interface for commercially available
inhaler device. The framework employs NETL developed CFD-DEM simulation code “MFiX” for
predicting the transport and deposition of DPI particle, ANSYS.INC developed engineering
simulation and 3D design software ANSYS for visualizing the fluid flow and particle movement
and Sandia developed “DAKOTA” for sensitivity analysis. There are lots of drug and carrier
particle information available in previous researches. This project is mainly focus on the particle
properties in DPI performances. After doing all parametric studies, cases has been setup for all
13

particle and fluids data variation for this project. Simulations will be done by using two CFD-DEM
simulation Codes such as MFiX & ANSYS. Input files needs to be created for MFiX simulations
by developing codes in C++. This code generates values of input variables and passes those input
variables to MFiX-DEM and launches MFiX simulations. After numerical calculations, ParaView
performs post-processing to extract the quantities of interest from MFiX–DEM results. After
obtaining all the data from MFiX and ParaView, particle data analysis will be done.

Figure 3.1: Project Schematic and simulation procedure based on the CFD-DEM method
14

Another simulation will be done using CFD-DEM simulation Code ANSYS which best
describes the flow field and particle tracking inside a computational domain. From geometry
creation to post-processing all can be done in this one software package. Same geometric
parameter and fluid and particle properties will be used in this software. After geometry and mesh
creation, input variables will be implemented in ANSYS FLUENT to run the case. When
calculations will be done then post-processing can be done in CFD-Post to get better idea of flow
field and particle movement inside the domain.
For the uncertainty quantification an interface between the MFiX and DAKOTA is created
via a C++ wrapper of MFiX-DEM simulations. This wrapper exchanges the information among
DAKOTA and MFiX–DEM for the uncertainty quantification. DAKOTA generates values of
uncertain input variables via upper and lower bounds and passes those input variables to MFiXDEM via the wrapper and launches MFiX simulations. DAKOTA receives response functions
from MFiX and performs the uncertainty quantification. Then performs post-processing to extract
the quantities of interest from MFiX–DEM results. In the input file for DAKOTA, the variables
with uncertainty and a range of values are used to determine the upper and lower bounds.
Present study deals with a dry particle inhaler (DPI) which is considered as a fluidized bed for
simulation eases. The schematic of a DPI computational domain and boundary conditions used in
this research is shown in Figure 3.2. The DPI device is considered as a fluidized bed where the
different types of particles will react, agglomerates and then leave the domain after a certain time.
Figure 3.2 shows the computational domain and boundary conditions for the DPI problem.
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Figure 3.2: Computational domain and boundary conditions for the DPI problem.
The geometrical dimensions of fluidized bed with other conditions used in this study are given
in Table 3.1.The parameters used in Table 3.1 will be same for MFiX and ANYS simulations.
Table 3.1: Particle properties with Geometric configuration of fluidized bed used for this project
Parameters

Value/Conditions

Bed length
Bed width
Solver
Inlet Condition
Outlet Condition
Wall
Discrete Element Method
Inlet DPM case
Outlet DPM case
Wall DPM case
Spatial Discretization
Particle stiffness coefficient
Particle friction coefficient
Fluid Velocity
Temperature
Gravity (in y direction)
Gas Viscosity

0.02m
0.01m
Pressure-based
Velocity Inlet
pressure outlet
No-slip
On
Escape
Escape
Reflect
First Order Upwind
1000 N/m
0.1 m
1-5 m/s
293.15 k
-9.81 m/s
1.81E-05 kg/m.s

Number of Particles

500 drug particle
500 carrier particle
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Several cases with change of fluid and particle properties (size, density) will be simulated
to analyze particle characteristics and their performances on lung deposition. All the cases will be
simulated in MFiX 18.1.0 software and the data from MFiX will be post-process via ParaView
5.6.0. More than 30 cases have been running yet and from data analysis of those cases, few cases
will be chosen that show better results with particle variations in this project. All of the cases are
shown in Table 3.2.
Table 3.2: Particle properties used in this research
Case
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
21
22
23
24
25
26
27
28

Drug Particle Diameter, µm
3.11
4.50
3.26
3.33
3.30
3.30
3.10
2.90
2.90
1.80
2.63
1.80
1.80
3.80
2.40
3.40
3.10
3.10
3.45
3.50
3.50
3.40
2.56
2.50
3.15
1.80
4.51
1.92
5.14
17

Carrier Particle Diameter, µm
56
63
63
63
63
63
69
63
63
72
59
71
52
48
51
50
53
5.1
41
54
61
43
53
59
56.9
41
71
51.3
63.7

29
3.04
42
30
3.66
47.3
31
1.74
64.2
Based on a wide range of particle data, overall particle performances will be measured as
a parameter of particle relaxation time, residence time, and diffusivity. Change of particle size will
directly impact the tangential and axial velocity components and all other particle properties. In
this research, a 2D full order high-fidelity CFD tool will be used to simulate the fluid and particle
flow inside a DPI device to evaluate different particle size options for optimizing particles
performances in terms of relaxation time, residence time, and diffusivity. After comparing all the
results, it will be simple to predict the best case scenario.
3.2.1: Modeling using MFiX:
We considered a fluidized bed in two dimensions in figure 3.3 shows for the DPI problem
created in MFiX. The length, width of the bed are 0.02 m and 0.01 m, respectively.

Figure 3.3: Computational domain for the DPI problem on MFiX. The figure is drawn to
scale.

The computational domain is discretized with 20 equi-spaced cells in the axial direction
(y-direction) and 10 equi-spaced cells in the normal direction (x-direction). Velocity along the x18

direction is specified on the bottom boundary. The pressure outflow condition is applied on the
top boundary. Initially, the bed is filled with 500 carrier particles of 52.5 𝜇𝑚 in size and density
of 2650 kg/m3 and 500 drug particles of 3.2 𝜇𝑚 in size and density of 1520 kg/m3. These particles
are fluidized with air of velocity 3 m/s, density 1205 kg/m3, and viscosity of 18 𝜇𝑃. 𝑠. Gravity is
considered. The stiffness coefficient of the particle is 1000 N/m. The friction coefficients of
particles is 0.1.

A 3D fluidized bed is also created and the data from 3D cases will be used in DAKOTA to
perform the uncertainty quantification. Then post-processes the data to extract the quantities of
interest from MFiX–DEM results. The length, width and height of the bed are 0.01 m, 0.01m and
0.02 m respectively.

Figure 3.4: Computational 3D domain for the DPI problem on MFiX. The figure is drawn
to scale.
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This 3D computational model will deal with approximately 8000 particles inside the
domain, so MFiX-PIC (particle in cell) solver is used in this case. For 2D cases, MFIX-DEM
(Discrete Element Method) is used because of it good fidelity and ability to model individual
particles of the solid phase. But for dealing with a large amount of particle, it is not user-friendly
and will require high performance computing (HPC) resources and lots of time. For this reason,
3D simulations for larger amount of particle use PIC model instead of DEM on MFiX.
Velocity along the x-direction is specified on the bottom boundary. The pressure outflow
condition is applied on the top boundary. The outlet is located on middle of the top boundary
where outlet dimension is 0.005*0.005 m. Same size of particles are used in both 2D and 3D cases.

3.2.2: Modeling using ANSYS:
The same fluidized bed with same dimension is considered but with different software
which is shown in Figure 3.5. ANSYS is used to visualize the fluid flow inside the domain. The
length, width of the bed are 0.01 m and 0.02 m respectively. The computational domain is created
with ANSYS Workbench and meshing has been done using ANSYS MESHING. Cells are
discretized with Global Coordinate Method. All quadrilateral type of mesh is created with Mapped
facing option that will ensure smooth flow into the domain. Total 222111 elements with 223112
nodes have been created for fine meshing. Velocity along the x-direction is specified on the bottom
boundary. The pressure outflow condition is applied on the top boundary. The mesh operation
was done at the end to make the geometry prepared for numerical fluid flow analysis within the
area. When the geometry has a finer mesh with no skewed elements then fluid flow inside an
inhaler device can be solved in ANSUS FLUENT 15.0. A commercially available CFD code,
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FLUENT is used to solve the discretized equations (conservation of mass, momentum and energy
equations) by finite volume formulation.

Figure 3.5: (a) Computational domain and (b) mesh generation for the DPI problem. The figure
is drawn to scale.
Once the modeling had done, boundary condition was implemented. In this study, a
velocity inlet boundary condition is applied at inlet; pressure outlet BC at outlet and no slip BC at
the walls. Air was considered as continuous phase material in this study. The Eulerian-Lagrangian
approach has been employed to simulate the DPI device. Numerical simulations were done by the
Eulerian reference frame for continuous gas phase flow and by Lagrangian method for dispersed
phase particle trajectories. 3-D, unsteady and incompressible fluid flow in Eulerian formulation
is introduced in this investigation. The Lagrangian approach resolves the transport equations of
continuous phase in Eulerian frame and then integrates the dispersed phase equations by
tracking individual spherical particles through the converged flow field. The stochastic Particle
Tracking Model outlined the particle motions by tracking particle trajectories in Lagrangian frame
of reference. By keeping track on the number of particles escaping through the outflow, the
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particle performance could be measured. There are a lot of turbulence model available in FLUENT
solver. As other models (i.e.-ɛ, k-omega) models have some limitations to swirling turbulent flow,
so for simple flow field, laminar model is used in this simulation. The fluctuating gas velocities
can be determined by using a discrete random walk (DRW) model which is based on the stochastic
tracking scheme.
The Phase coupled SIMPLE (Semi-Implicit Method for Pressure-Linked Equations)
scheme for pressure – velocity coupling has been used in finite volume method to discretize the
partial differential equations and second order upwind scheme is used in the solution method for
the control volume variables. The inlet velocity is considered as 3 m/s for this study .The maximum
number of integration steps were 5 × 105 and a length scale of 0.005m were chosen for the
dispersed particle trajectories. Particle time step size of 0.001s with an automated tracking scheme
was selected for the numerical experiments and an accuracy of 10−5 was performed for accuracy
control.
3.4: Summary:
This chapter provides a high level description of the objective of this research. It discusses
about the framework that employs NETL developed CFD-DEM simulation code “MFiX” for
predicting the transport and deposition of DPI particles and Sandia develop “DAKOTA” for
sensitivity analysis. This chapter also discusses about a 2D fluidized bed domain and its different
boundary conditions for MFiX and ANSYS simulation. There will be different cases with the
change of boundary conditions such as, change in particle size, density and also change in fluid
properties.
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Chapter 4: Methodology
4.1: Introduction:
Several commercial packages are available for analyzing computational modeling
problems associated with fluid dynamics applications. Despite the advancement of computational
modeling packages, there are lots of challenges in resolving physics in a large computational
domain with plenty resolutions. This research will influence exascale capable CFD-DEM and
sensitivity analysis capabilities from Department of Energy (DOE) laboratories: Multiphase Flow
Interface Flow Exchange (MFiX) and DAKOTA UQ software, and Trilinos portable scalable
linear algebra libraries. In this chapter, we will discuss details about these softwares and their
implementation in computational modeling. One of the software used in this study is MFiX that
has generally been a popular CFD library to solve fluidized bed problems. Even though MFiX has
been developed on a parallel FORTRAN platform, it has limitations with scalability issues for
large and non-linear problems. In that regard, DAKOTA provides flexible and extensible problemsolving capabilities on high-performance computer and creates a flexible interface between
simulation codes and analysis methods. Moreover, Trilinos has been explored for its scalability
performance on dealing with linear algebra objects and state-of-the-art linear solver capabilities.
The Trilinos library is integrated with MFiX in order to exploit the scalable linear algebra package
in MFiX.
4.2

MFiX
MFiX is a widely used by the fossil fuel reactor communities to model and understand the

multiphase physics in a circulating fluidized bed. In MFiX, the interactions between gas-solids are
addressed by the solving the coupled continuity and momentum conservation equations
simultaneously. The momentum conservation equations involve interaction force, or momentum
transfer, between the gas phase and the various solids phase. From studies on the dynamics of a
particle, several mechanisms, such as electrostatic forces, van der Waals force, drag force,
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buoyancy, virtual mass effect, lift force, Magnus force, Basset force, Faxen force, and forces
caused by temperature and density gradients, play important role in modeling multiphase flows.
Several other factors, however, need to be considered when the formulas for a single particle
system are generalized to describe interaction forces in real life multi-particle systems such as: 1)
the effect of the proximity of other particles must be accounted for; the single-particle interaction
force must be corrected to account for the effect of mass transfer between the phases, as in the case
of coal devolatilization or combustion, for example; 2) the momentum transfer accompanying
such mass transfer must be included in the interaction force; and 3) the formulations for fluidsolids drag deal with uniform, smooth, spherical particles, whereas practical fluid-solids systems
contain rough, non-spherical particles of different sizes [63]. The particle-size distribution can be
characterized by an average size based on particle surface area. A broad particle-size distribution
can be discretized into two or more particle surface area, each characterized by an average size.
The effect of non-sphericity and roughness effects on drag are implicitly contained in the
momentum conservation equations, but it may be appropriate to explicitly account for the particle
interactions on the fluid-solids interaction force for non-spherical particles through a new drag
model. Fluid-particle and particle-particle forces can be separated in two terms. Averaging the
particle to granularize the system makes the hydrodynamic solver incapable of resolving small
scale phenomena such wake-dominated features near the particles. In fossil energy applications,
for example, gaseous molecules are produced and participate in radiant heat transfer as a result of
thermal radiation with vibrational and rotational modes of energy absorption. The solid particles
during this process also plays a major role in radiative heat transfer since the coal particles will go
through preheating, devolatization, ignition and partial combustion process.
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The state of art of multiphase flow is relatively new and not well understood. In DPIs, for
example, APIs and carrier particles flows in a dense gas-solids mixture. The coupled physics
include hydrodynamics, shear forces, and reaction kinetics. The coupled physics would clearly
influence the performance of DPIs. Design of operational DPIs has traditionally relied on lab-scale
experiments as pilot-scale units and clinical trials that are expensive to build and operate and
provide limited insight.

In DEM approach, the gas-phase governing equations for mass and momentum
conservation are like those in traditional gas-phase CFD but with additional coupling terms due to
drag from the solids phase. The solids-phase is modeled using discrete particles. The governing
equations [64,65] for the gas-phase continuity and momentum conservation in the absence of phase
change, chemical reactions, growth, aggregation, and breakage phenomena, are:
𝜕(𝜀𝑔 𝜌𝑔 )
𝜕𝑡
𝐷
𝐷𝑡

+ ∇. (𝜀𝑔 𝜌𝑔 𝑣𝑔 ) = 0,

(4.1)

(𝜀𝑔 𝜌𝑔 𝑣𝑔 ) = ∇. ̿̿̿
𝑆𝑔 + 𝜀𝑔 𝜌𝑔 𝑔 − ∑𝑀
𝑚=1 𝐼𝑔𝑚 ,

(4.2)

where, subscript g represents a fluid variable, subscript s represents the quantity belongs to
the solid phase, ε is the volume fraction, ρ is the thermodynamic density, v is the volume-averaged
gas-phase velocity, Igm accounts the momentum between the fluid phase and the mth solid phase,
buoyancy, and drag force, among others, and ̿̿̿
𝑆𝑔 is the stress tensor. The stress tensor is given
by ̿̿̿
𝑆𝑔 = −𝑃𝑔 𝐼 ̅ + 𝜏̿𝑔 , where P is the pressure and, 𝜏̿𝑔 is the stress tensor. The stress tensor is
1

𝑇

̿̿̿𝑔̿ + λ𝑔 ∇. tr(𝐷
̿̿̿𝑔̿) I, where (𝐷
̿̿̿𝑔̿)= [∇𝑣𝑔 + (∇𝑣𝑔 ) ] is the strain rate tensor
defined as𝜏̿𝑔 = 2 𝜇𝑔 𝐷
2
and 𝜇𝑔 and λ𝑔 are the dynamic and second coefficients of viscosity. Conservation of species,
internal energy, granular energy as well as correlations that model the flow at all ranges of
Reynolds numbers can be found in [66–68].
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In DEM approach, the mth soild-phase is represented by Nm spherical particles with each
having diameter D and density ρ. Solid phases are differentiated based according to radii and
densities. The diameter and density of the mth solid-phase is denoted by Dm and ρsm, respectively.
For total of M solid phases, the total number of particles is equal to N = ∑𝑀
𝑚=1 𝑁𝑚 . These N
particles are represented in the Lagrangian frame of reference at time t by {X(i)(t), V(i)(t), ω(i)(t),
D(i)(t), ρ(i), i=1,…,N}, where X(i) denotes the ith particle's position, and V(i) and ω(i) represents its
linear and angular velocities. The mass m(i) and moment of inertia I(i) of the ith particle are equal to
𝜌(𝑖) 𝑚𝐷(𝑖)3 /6 and 𝑚𝐷(𝑖)2 /10, respectively. The position, linear and angular velocities of the
ith particle are calculated according to Newton’s laws
𝑑𝑋 (𝑖)
𝑑𝑡
𝑚(𝑖)

𝑑𝑉 (𝑖) (𝑡)
𝑑𝑡

𝐼

(𝑖)

= 𝐹𝑇
(𝑖)

== 𝑉 (𝑖) (t)
(𝑖∈𝑘,𝑚)

= 𝑚(𝑖) 𝑔 + 𝐹𝑑

(4.3)
(𝑡) + 𝐹𝑐 (𝑡)

(4.4)

𝑑𝜔 (𝑖) (𝑡)
= 𝑇 (𝑖)
𝑑𝑡

(4.5)
(𝑖∈𝑘,𝑚)

where, g is the acceleration due to gravity, 𝐹𝑑

(𝑡) is the drag force due to pressure
(𝑖)

and viscosity on ith particle residing in kth cell and belonging to the mth solid-phase, 𝐹𝑐

is the net

contact force acting because of contact with other particles, T(i) is the sum of all torques acting on
(𝑖)

the ith particle, and 𝐹𝑇 is the net sum of all forces acting on the ith particle.
To resolve the particle–particle and particle–wall collisions, a soft-spring model [69] is
used. The details of the soft-spring mode implementation along with other numerical and
implementation details can be found in the MFIX–DEM documentation [70]. Since a spring–
dashpot combination is used in soft-spring model, it leads to introduction of several numerical
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parameters (such as, spring stiffness coefficient, damping coefficient, etc.) that are related to
physical parameters such as coefficient of restitution, coefficient of friction, etc.
For simulating multi-phase flow, MFiX has three numerical models: Two-Fluid Model
(TFM), Discrete Element Model (DEM) and the Particle in Cell Model (PIC). TEM and PIC both
are Eulerian-Eulerian model while DEM is an Eulerian-Lagrangian model, where instead of using
the finite-volume-method, the second phase (typically solid particles) are treated as particles. The
governing equations for such flows are given by the phasic volume fractions of each phase are as
follows,
𝜖𝑔 + ∑𝑀
𝑚=1 𝜖𝑠𝑚 = 1

(4.6)

Here, 𝑔, 𝑠 and 𝑚 denote the gas phase, the solid phase and the 𝑚𝑡ℎ solid phase in the mixture of
fluids. The effective densities of the gas and solid phases are given as
𝜌𝑔′ = 𝜖𝑔 𝜌𝑔

(4.7)

′
𝜌𝑠𝑚
= 𝜖𝑠𝑚 𝜌𝑠𝑚

(4.8)

′
Here, 𝜌𝑔′ and 𝜌𝑠𝑚
are effective densities while 𝜌𝑔 and 𝜌𝑠𝑚 are their actual densities.

The continuity equations for the gas and the solid phase 𝑚 are given as
𝜕

(𝜖𝑔 𝜌𝑔 ) + 𝛁. (𝜖𝑔 𝜌𝑔 𝒗𝒈 ) = ∑𝑁
𝑛=1 𝑅𝑔𝑛

(4.9)

(𝜖𝑠𝑚 𝜌𝑠𝑚 ) + 𝛁. (𝜖𝑠𝑚 𝜌𝑠𝑚 𝒗𝒔𝒎 ) = ∑𝑁
𝑛=1 𝑅𝑠𝑚𝑛

(4.10)

𝜕𝑡
𝜕
𝜕𝑡

The first and second terms on the left sides of the equations are the rate of mass generation per
unit volume and the net rate of convective mass flux. The terms of 𝑅𝑔𝑛 and 𝑅𝑠𝑚𝑛 on the right sides
account for interphase mass transfer due to chemical reactions or physical processes.
The momentum equations are given as
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𝜕
𝜕𝑡

(𝜖𝑔 𝜌𝑔 𝒗𝒈 ) + 𝛁. (𝜖𝑔 𝜌𝑔 𝒗𝒈 . 𝒗𝒈 ) = 𝛁. (𝑆𝑔 ) + 𝜖𝑔 𝜌𝑔 𝑔 − ∑𝑀
𝑚=1 𝐼𝑔𝑚 + 𝒇𝒈

(4.11)

𝑀

𝜕
(𝜖 𝜌 𝒗 ) + 𝛁. (𝜖𝑠𝑚 𝜌𝑠𝑚 𝒗𝒔𝒎 . 𝒗𝒔𝒎 ) = 𝛁. (𝑆𝑠𝑚 ) + 𝜖𝑠𝑚 𝜌𝑠𝑚 𝑔 − ∑ 𝐼𝑚𝑙 + 𝐼𝑔𝑚 + 𝒇𝒈 (4.12)
𝜕𝑡 𝑠𝑚 𝑠𝑚 𝒔𝒎
𝑙=1,𝑙≠𝑚

The first terms on the left sides of equations are the net rate of momentum generation and the
second terms are the net rate of momentum transfer by convection. These include the gas phase
and solid phase stress tensors 𝑆𝑔 and 𝑆𝑠𝑚 , the body forces due to gravity 𝑔, the flow resistance
force 𝑓𝑔 due to internal porous surfaces, the interaction force 𝐼𝑔𝑚 accounting for the momentum
transfer between the gas phase and the mth solid phase, and the interaction force 𝐼𝑙𝑚 between the
𝑚𝑡ℎ and 𝑙 𝑡ℎ solid phases.
4.3

DAKOTA
UQ strategies are sorted by their capacity to spread aleatory or epistemic information

vulnerability portrayals, where aleatory vulnerabilities are final changeability inalienable in nature
and epistemic vulnerabilities are reducible vulnerabilities coming about because of an absence of
information. Since adequate information is by and large accessible for aleatory vulnerabilities,
probabilistic strategies are generally utilized for processing reaction appropriation measurements
considering information likelihood conveyance. Then again, for epistemic vulnerabilities, any
utilization of likelihood conveyances depends on subjective information instead of target
information, and we may on the other hand investigate nonprobabilistic strategies considering
interim. The aleatory UQ techniques in DAKOTA incorporate different testing-based
methodologies (e.g., Monte Carlo and Latin Hypercube inspecting), neighborhood and global
unwavering quality strategies, and stochastic extension (polynomial mayhem developments and
stochastic collocation) approaches. The epistemic UQ techniques incorporate nearby and global
interim investigation and Dempster-Shafer confirm hypothesis.
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DAKOTA [71] is a toolkit that provides a flexible and extensible interface between
simulation codes and analysis methods. It contains algorithms for optimization; uncertainty
quantification with sampling, reliability, and stochastic expansion methods; parameter estimation
with nonlinear least squares methods; and sensitivity analysis with design of experiments and
parameter study methods. These capabilities are used in various optimization models. The toolkit
provides flexible and extensible problem-solving capabilities on high-performance computers as
the main components for the iterative system analyses are designed with an object-oriented
framework. In the present work, DAKOTA will used to perform the uncertainty quantification
[72]. A schematic of the software integration is shown in Figure 4.1. CFD-DEM will be simulated
for various API and carrier particles size. For example, in jet nebulizer particle delivery method,
budesonide particle size of 3.8-5.5 μm [73] at 1.3±0.1 g/cm3 are used via liquid-air particle
distribution mechanism whereas in DPI, API particle sizes between (1–5) μm [74] are used via
solid particle-air mechanism.
4.4

Framework to Incorporate MFiX with Dakota
An interface between MFiX and DAKOTA is created via a C++ wrapper which can be

seen in Fig. 4.1 [75]. This C++ wrapper is used to exchange the information between DAKOTA
and MFiX and DAKOTA is the primary driver in this current framework, which generates values
of uncertain input parameters. These values are used in making the input file for simulations with
MFiX. The wrapper launches MFiX simulations and calculates the response functions. The
response functions are returned to DAKOTA for calculating the low order statistics of the response
functions. In DAKOTA input file, we define the parameters with uncertainty and their range.
Besides, response functions and a UQ method to be employed are also specified in this input file.
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Figure 4.1: A framework to implement MFiX in DAKOTA via a C++ wrapper75.
The wrapper creates a directory for a sample point or each independent run and makes the
input file for MFiX simulations. The MFiX input file includes the values of the uncertain input
parameters from DAKOTA. The values of these parameters are based on the upper and lower
bounds and the probability distribution function. The wrapper launches MFiX executable for each
sampling point and calculates the response function(s) when the input file for MFiX simulations
is made.
The response functions derived at the end of MFiX simulations for all the sampling points
are used to calculate the low order statistics with DAKOTA. The C++ wrapper is integrated with
DAKOTA via the fork interface. The fork/exec interface in DAKOTA return a process identifier
that the wait functions can use to detect the completion of a simulation for either synchronous or
asynchronous operations. The interface avoids the potential of a file race condition when
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employing asynchronous local parallelism. This condition can occur when the responses file has
been created, but the writing of the response data set to this file has not been completed. It has
additional asynchronous capabilities when a function evaluation involves multiple analyses. The
fork interface supports asynchronous local and hybrid parallelism modes for managing concurrent
scans within function evaluations.
4.5

ANSYS:
The numerical analysis of fluid flow gives us an extensive idea of the Computational Fluid

Dynamics (CFD), which becomes a great concern to engineers and scientists. CFD owes its
popularity for predicting fluid flow, heat transfer, and chemical species transport in different
environmental condition analysis [76]. With the advent of powerful parallel computers and
advances in computational techniques in recent years, CFD gives quantitative and qualitative
analysis of fluid flow that is able to deal with the real life problems with better accuracy [77].
In this numerical analysis-based work, several cases for different particle size and different
velocity on a DPI device will be discussed. To get the best aerosol particle delivery into the
pulmonary system, a comparison needs to be made based on all the particle and flow parameters.
It would take a huge cost to check all these cases in practical life. Therefore, numerical analysis
provides a guideline to choose the best experimental setup to make it more cost effective [78].
The flow field inside DPI is a complex phenomenon in fluid dynamics problem. A
combined approach on CFD and discrete element method (DEM) is exhibited on this project which
explains the particle-particle and particle-fluid interactions [79-90]. For better understanding of
complex particle-fluid flow, CFD–DEM approach has been extended in several studies on the gas–
solid ﬂow on inhaler device [91-95]. CFD analyzes the fluid dynamic phenomena by using
numerical methods. Fluid Dynamics (FD) solution can be obtained by sets of governing equation.
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Navier–Stokes equation controlled the gas phase simulation in CFD–DEM modelling [96]. The
Navier–Stokes equations are nonlinear partial differential equations that illustrates the
conservation of linear momentum for a linearly viscous (Newtonian), incompressible fluid flow
[97, 98]. Density does not vary with the fluid motion in an incompressible flow.
4.5.1 Grid Generation
Grid is generated in ANSYS WORKBENCE software for the CFD solver. Discrete domain
with grid can replace the continuous domain for CFD simulation. In continuous domain, each flow
function can be outlined at every point of the domain. On the other side, each flow function is
defined at the grid points only in discrete domain. The discrete system is a set of coupled, algebraic
equations in the discrete variables. Discrete system includes a very large number of iterative
calculations which is done by the digital computer. Figure 4.2 shows the pressure (p) variable in
1D continuous and discrete domain. It can be said from the figure that the pressure would be
defined only at the N grid points in terms of discrete domain where, pi = p (xi); i = 1; 2; N and for
continuous domain, it would be, p = p(x); 0 < x < 1.

Figure 4.2: Examples of continuous domain and discrete domain
Grid, a discrete geometrical representation, divides the computational domain into cells or
elements on which the flow and differential problem can be solved in a most accurate and effective
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way. Success of the CFD analysis lies on the design and construction of a quality grid. Solution
accuracy and rate of convergence is dependent on the grid size. Higher accuracy can be obtained
by building finer mesh. Coordinate system gives points and directions to make a grid point. Cells
are grouped into boundary zones where B.C.s is applied. Structured and unstructured, both grids
are used on computational domain. Structured grid can’t be used on complex geometries. A regular
pattern grid arrangement is called structured grid, while irregular pattern arrangement is called
unstructured grid. Unstructured grid is commonly used with the finite element method. We have
used structured hexahedral grid on this dissertation. Depending on the solver capability and
problem settings, different types of grid are used on numerical analysis. Both 2D and 3D grid can
be generated in ANSYS software. 2D grid takes less memory and less time to perform numerical
analysis. A 2D grid usually considers no velocity gradients in the direction normal to the grid. 3D
grid generation is the most time consuming part of the 3D simulation calculation. It takes longer
computational time than 2D grid generation.

Figure 4.3: Different types of grid (a) 2D grid, (b) 3D grid
Governing equations are not good enough to get analytical solutions of fluid flow or heat
transfer problem. Finite volume method can solve the partial differential equations on fluid flow
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analysis. To analyze fluid flow inside a computational domain, the domain is discretized into
smaller volumes or subdomains. Then the governing equations solve every discretized volume.
These discretized subdomains are called elements or cells and the set of all elements are called
mesh. Appropriate choice of mesh will impede the simulation error and can give us an accurate
result during the flow analysis in Fluent.
4.5.2 Numerical Modeling

A highly reliable CFD modeling can help us to understand the physics inside the
flow field of DPI sampler. Appropriate computational modeling is essential to comprehend the
flow physics of the system and determine the underlying methodology of CFD. It can accurately
predict the behavior of flow with the help of powerful digital computers. The numerical solution
of computational flow modeling includes resolving the fluid dynamics phenomena in details. Grid
refinement is important to determine the ordered discretization error in CFD simulation.
Computational problem size can be augmented by grid refinement which will increase the need
for parallel computing. The multiphase flow considered here is isothermal system which does not
involve temperature change, even though temperature variation could play a role to change the
deposition of particle inside the tube. The flow is 3D incompressible gas-droplet/particle twophase interactions.

Turbulence models are based on statistical analysis as it is becoming an interesting
alternative on CFD modelling. In past years, different turbulent models, e.g. standard 𝑘 − 𝜖 model,
𝑘 − 𝜔 model, and RNG 𝑘 − 𝜖 have been applied to RANS to model DPI flow inside the
separator/sampler [99]. Large disparate results compared to experimental data have been reported
in published literature (e.g. Chen 1997). For this reason, different turbulent models have been
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justified for DPI flow as a first step of the design evaluation. On the other hand, the numerical
simulation efficiency mainly depends on the form of the turbulence modelling. As standard k–ɛ
turbulence model conducts to impracticable tangential velocities and enormous turbulent
viscosities, previous studies indicate the inability of standard k–ɛ turbulence model to simulate the
highly swirling turbulence flow [100]. Since Reynolds stress turbulence model (RSTM) justifies
the stream curvature effects, rotation and the swirling flow effects, this (RSTM) model is
appropriate for highly anisotropic flows. But to observe a simple, smooth flow field inside
fluidized bed, Laminar model is used in this case. Velocity fluctuation profiles will describe
fundamental mechanism inside the fluidized bed.

4.5.3 Mathematical Modelling:
Computational fluid dynamics (CFD) method is used to model the performance of a DPI and
it can anticipate the flow field characteristics and the particle trajectories inside the inhaler. The
intricate turbulent flow in a DPI places great demands on the numerical techniques and the
turbulence models employed in the CFD codes when modelling the DPI performance.
FLUENT uses a finite volume method (FVM) to solve the governing equations. Reynoldsaveraged Navier-Stokes equations (RANS) for steady and incompressible fluid flow can be
expressed as:
𝜕𝑢

𝜕𝑝

𝜕

𝜕𝑢

𝜕𝑢

𝜌𝑢𝑗 𝜕𝑥 𝑖 = − 𝜕𝑥 + 𝜕𝑥 [𝜇 (𝜕𝑥 𝑖 + 𝜕𝑥𝑗)] +
𝑗

𝑖

𝜕𝑢𝑖
𝜕𝑥𝑖

𝑗

𝑗

𝑖

𝜕𝜏𝑖𝑗
𝜕𝑥𝑗

=0

(4.13)
(4.14)

where, the superscripts i, j = 1, 2 represent the Cartesian coordinate system components,
𝜌, 𝑢, 𝑝 𝑎𝑛𝑑 μ is the fluid density, velocity, pressure and viscosity respectively and

𝜏𝑖𝑗 = −𝜌𝑢́𝑖 𝑢𝑗́

(4.15)
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which is defined as the Reynolds stress tensor that indicates the turbulent fluctuations effects
on the fluid flow. The dash and overbar represent the fluctuating part and a Reynolds average
term.

Reynolds stress model
The standard k-ɛ model is inappropriate due to its certain limitations in the case of strong
swirling flow [101]. Reynolds stress model (RSM) can solve the transport equations of Reynolds
stress model within particular stress components and improves the isotropic turbulence of k- ɛ
model. The transport equations of Reynolds stress (RSM) model can be written as follows:
𝜕𝜌𝑢𝑖 𝑢𝑗
𝜕𝑡

𝜕

𝜕

2

+ 𝜕𝑥 (𝑈𝑘 𝜕𝜌𝑢𝑖 𝑢𝑗 ) = 𝑃𝑖𝑗 + ∅𝑖𝑗 + 𝜕𝑥 [(𝜇 + 3 𝑐𝑠 𝜌
𝑘

𝑘

𝑘2
ɛ

)

𝜕𝜌𝑢𝑖 𝑢𝑗
𝜕𝑥𝑘

2

] − 3 𝛿𝑖𝑗 𝜀𝜌
(4.16)

where, k is the turbulent kinetic energy, ɛ is the dissipation rate of k, pressure-strain correlation
is expressed in ∅𝑖𝑗 terms and 𝑃𝑖𝑗 is the production term of 𝑢𝑖 𝑢𝑗 which can be written as follows:
P = -ρ (𝑢. 𝑢(∇𝑈)𝑇 + (∇ 𝑈)

(4.17)

The turbulent dissipation rate presents within the individual stress equations. The equation for
the turbulent dissipation rate ɛ is given as:
𝜕𝜌𝜀
𝜕𝑡

+ ∇. (ρ Uε) =

𝜀

(𝑐 𝑃 − 𝑐𝜀2 ) + ∇. [𝜎
𝑘 𝜀1

1

𝜀𝑅𝑆

(𝜇 + 𝜌𝐶𝜇𝑅𝑆

𝑘2
𝜀

) . 𝜀]

(4.18)

The model constants in these equations are
𝑐𝑠 = 0.22; 𝑐𝜀1 = 1.45; 𝑐𝜀2 = 1.9; 𝑐𝜇𝑅𝑆 = 0.115

Model Equations for Particle Motion
The equation of dispersed particles motion can be by integrating the force balance equation in
a Lagrangian reference frame. FLUENT anticipates the trajectory of a discrete phase in a
Lagrangian reference frame [102]. The force balance equation of a single dispersed particle can
be written (for the x direction in Cartesian coordinates) as
𝑑𝑢𝑝
𝑑𝑡

𝑔𝑥 (𝜌𝑝 – 𝜌)

= 𝐹 d (u - up)

𝜌𝑝

+ Fx

(4.19)

where, Fx is an additional acceleration term , u is the fluid phase velocity, up is the particle
velocity, 𝜌p is the density of the particle, 𝑔𝑥 is the gravitational acceleration and Fd (u-up) is the
drag force per unit particle mass where Fd can be written as [49]:
36

18𝜇

𝐹𝐷 = 𝜌

𝑝 𝑑𝑝

𝐶𝑑
2

24

𝑅𝑒

(4.20)

Here, 𝜇 is the molecular viscosity of the fluid, 𝜌 is the fluid density, dp is the particle diameter
and drag coefficient Cd can be determined by Morsi and Alexander’s correlation. Re is the relative
Reynolds number, which is defined as,

Re =

𝜌 𝑑𝑝|𝑢 −𝑢|
𝑝
𝜇

(4.21)

Saffman’s Lift Force
The Saffman's lift force (lift due to shear) can also be included in coupled force term. The
Saffman lift force is a generalization form from Li and Ahmadi which can be written as:
𝐹⃗ =

2𝐾𝑣 1/2 𝜌𝑑𝑖𝑗
𝜌𝑝 𝑑𝑝 (𝑑𝑙𝑘 𝑑𝑘𝑙 )1/4

(𝑣⃗ − 𝑣⃗𝑝)

(4.22)

where, k = 2:594 and dij is the deformation tensor. This form of the lift force is intended for
small particle Reynolds numbers.
4.5.4 BOUNDARY CONDITIONS
Boundary conditions (BC) are a set of conditions that specify the flow and thermal
variables at the boundary of its domain. These are verily important parameter for the mathematical
model and FLUENT simulations [103]. Without appropriate boundary condition settings,
numerical simulation would not be able to solve the flow analysis. CFD requires proper boundary
condition on the outer and inner surfaces of the fluid domain, while the inner surfaces represent
fluid-structure interfaces [104]. In general, boundary conditions are two types i.e.

i.

Dirichlet boundary conditions – specify the value of the variable at the boundary,
e.g. 𝑢(𝑥) = 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡
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ii.

Neumann boundary conditions – specify the gradient normal to the boundary of
the variable at the boundary, e.g. 𝜕𝑛 𝑢(𝑥) = 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡

iii.

Robin boundary conditions- specify a linear combination of the values of a
function and the values of its derivative on the boundary of the domain on an
ordinary or a partial differential equation. If Ω is the domain of a given equation to
be solved and ∂Ω represents its boundary, then the Robin boundary condition can
∂u

be expressed as: 𝑎𝑢 + 𝑏 ∂n = 𝑔 𝑜𝑛 𝜕𝛺 where, a and b are some non-zero constants
/wand a given function g defined on ∂Ω, ∂u/∂n is the normal derivative at the
boundary and u is the unknown solution defined on Ω.

Usually boundary conditions depend on the type of analysis (incompressible or
compressible). Another type of boundary condition is used to analyze fluid dynamics problem is
called mixed type boundary conditions. These types of boundary condition specify a function of
the form 𝑎𝑢(𝑥) + 𝑏𝜕𝑛 𝑢(𝑥) = 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 at the boundary. Proper boundary conditions give an
accurate solution of numerical simulation. Boundary conditions used at each face of each
computational domain. It specifies physical conditions (e.g. solid wall, symmetry plane, etc.) in
the boundary region and interfaces between contiguous or overlapped domain [105]. Inaccurate
boundary condition settings can lead to a nonphysical simulation results. Therefore, defining
proper and effective boundary condition is the most important part of CFD analysis.

For this research, we have used four different boundary conditions, i.e., velocity inlet at
inlet, pressure outlet at outlet, wall for boundary wall and interior BC for the interior zone. As
discrete phase calculations are accountable in this work, so discrete phase conditions will be
included in every boundary conditions.
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i.

Velocity inlet: Velocity inlet BC defines the velocity vectors and scalar properties of the
flow at flow inlets. Since the total (or stagnation) properties of the flow are not fixed, their
values may vary to give the recommended velocity distribution.

ii.

Pressure Outlet: Pressure Outlet BC is used when the flow velocity and pressure are
known before. Other flow variables are extrapolated from the interior. This boundary
condition requires the specification of a static (gauge) pressure at the outlet boundary. The
value of the specified static pressure is used only for subsonic flow. In case of supersonic
flow, the specified pressure will no longer be used; instead the pressure will be extrapolated
from the flow in the interior.

iii.

Wall: Wall BC is used to bound fluid and solid regions. No-slip BC is implemented on the
wall in viscous flow. Based on flow field details inside the computational domain, the shear
stress and heat transfer between the fluid and the wall are calculated.

iv.

4.6

Interior: Interior BC is used on flow fluid through an area.

Tensorflow
TensorFlow is an open source library that uses dataflow graph to represents a computation.

It was developed by the Google Brain team for implementing and distributing large-scale machine
learning models [106]. It supports a broad range of models efficiently including other types of
learning algorithms by distributing computations across thousands of multi-GPU servers and used
in computer vision, speech recognition, natural language processing, and text mining. Nodes in
the dataflow graph shows numerous operations including mathematical functions such as addition
and matrix multiplication; constant, sequence, and random operations for initializing tensor values;
summary operations for producing log events for debugging; and variable operations for storing
model parameters [107]. Therefore, TensorFlow is an interface for machine learning algorithms
and an application for implementing such algorithms on various heterogeneous systems.
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C++ wrapper creates an interface between TensorFlow and DAKOTA. This wrapper
interchanges the data among DAKOTA and TensorFlow. DAKOTA creates uncertain input
parameters values and provides those to TensorFlow. The wrapper launches TensorFlow and
guides the machine learning algorithm with the data created from DAKOTA-MFiX simulations
[75]. Then the algorithm predicts the quantities of interest (QoIs) for the dataset. The wrapper go
back to the predicted values and DAKOTA connects the wrapper through the fork interface. The
wrapper invokes TensorFlow or MFiX via the system functions. A framework to integrate
DAKOTA with TensorFlow is shown in Figure 4.4.

Figure 4.4: A framework to implement TensorFlow with DAKOTA via a C++ wrapper75

4.8

Summary
A novel high fidelity CFD discrete element modeling (CFD-DEM) method and sensitivity

analysis will be used for predicting the transport and deposition as well as the agglomeration and
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deagglomeration for DPI carrier and API particles. The CFD-DEM algorithm models
agglomeration and deagglomeration forces with MFiX. A model validation with available data
from the literature for DPI needs to be done with MFiX and ANSYS code and a sensitivity analysis
of various formulation properties and their effects on particle size distribution needs to conduct
with DAKOTA. MFiX has been developed by National Energy Technology Lab for fossil energy
applications and brings cutting CFD-DEM capabilities. Trilinos and DAKOTA have been
developed by Sandia National Labs and bring state-of-the-art exascale capable portable and
scalable linear solver and UQ capabilities. MFiX, Trilinos, and DAKOTA are open source
software and written for exploiting High-Performance Computing capabilities of a massively
parallel supercomputer, while ANSYS needs licensing for using it.

41

Chapter 5: Results and Discussion
We considered a fluidized bed with central jet in two dimensions. The flow in a fluidized
bed of 15cm width 90cm height is simulated with DEM model in MFiX. Initially, the half of the
bed is filled with sand particles of size 0.04cm and density of 2.7g/cm3. The void fraction at
minimum fluidization of the bed is 0.42. The spherical particles of size 4mm are fluidized with air
of density of 0.0012g/cm3 and viscosity of 0.00018Poise. The particle-particle restitution coefficient is 0.9 while the particle-wall restitution co-efficient is 1.0. The stiffness co-efficient of
particle is 800 N/m. The damping and friction coefficients of particles are 0.18 Ns/m and 0.3,
respectively. The flow is assumed to be laminar as well as incompressible. The computational
domain is discretized with 45 equi-spaced cells in the axial direction and 15 equi-spaced cells in
the normal direction. Constant mass flow and pressure boundary condition is specified on the
bottom and top boundary, respectively. The central jet velocity is 4200cm/s. The sparse linear
system of equation resulted from the discretizing the Navier-Stokes equations with SIMPLE
method are solved with Bi-Conjugate Gradient Stabilized (BiCGStab) method in MFiX. The flow
(volume fraction) in the fluidized bed at time t=20 and t=30 is shown in Figure 5.1. The time
histories of the bed height are also shown in the figure. The bed height (h) is defined at h(t) =
𝑁

𝑝
∑𝑛=1
𝑌 𝑛 /𝑁𝑝 where, 𝑁𝑝 is the number of spherical particles and Y is the location of the particle

in y-direction.
5.1: FLOW IN A FLUIDIZED BED WITH MFIX AND DAKOTA INTERFACE:
An interface between the MFiX and DAKOTA is created via a C++ wrapper for the
uncertainty quantification of MFiX-DEM simulations. This wrapper exchanges the information
among DAKOTA and MFIX–DEM for the uncertainty quantification. In the current framework,
DAKOTA is the primary driver, i.e., it generates values of uncertain input variables via upper and
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lower bounds and passes those input variables to MFiX-DEM via the wrapper and launches MFiX
simulations. DAKOTA receives response functions from MFiX and preforms the uncertainty
quantification. Then performs post-processing to extract the quantities of interest from MFIX–
DEM results. In the input file for DAKOTA, we prescribe the variables with uncertainty and a
range of values to determine the upper and lower bounds. In addition, the response variables with
the type of uncertainty quantity analysis to be performed are also specified in this input files.

Figure 5.1: Flow in a fluidized bed with central jet: (a) Volume fraction fields at time t=20 (b)
volume fraction fields at time t=30, and (c) time histories of the bed height
DAKOTA creates a directory for each independent run or a sample point and modifies the
input file for MFiX simulations by substituting new set of values from DAKOTA for the uncertain
variables considered in the MFiX-DEM simulations. The values for these variables are determined
based on factors such as the sampling method chosen, number of samples, upper and lower bounds
and the probability distribution function prescribed for the uncertain variable(s) in the DAKOTA
input file. DAKOTA launches MFIX–DEM executable for each sample independently. The
uncertainty quantification results with MFiX-DAKOTA framework for the fluidized bed with
central jet having two uncertain input variables are listed in Table 5.1. The average bed height
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decreases with the decrease in standard deviation of the input variables. Further, these results are
in good agreement with the results from MFiX-PSUADE framework [54] where ep,n is the particleparticle restitution co-efficient and ew,n is the particle-wall restitution co-efficient.
Table 5.1: Monte Carlo (MC) simulations with different standard deviation specifications for
input parameter distributions (based on 100,000 samples)
Case #

1
2
3
4

Input 1
e p,n

Input 2
e w,n

Ɲ(0.8,0.1) Ɲ(0.8,0.1)
Ɲ(0.8,0.05) Ɲ(0.8,0.1)
Ɲ(0.8,0.1) Ɲ(0.8,0.05)
Ɲ(0.8,0.05) Ɲ(0.8,0.05)

Avg.
Bed
height
Sample
mean
14.374
14.331
14.372
14.330

Avg. bed
height
Sample
Std
deviation
1.7e-01
7.5e-2
1.6e-1
7.5e-2

Figure 5.2 and 5.3 depict flow fields at time t=0.0s and 1.0s for different velocity directions.
The particle movement in fluidized bed can also be seen in the figures. The initial location of the
particles can be seen in the figures.

Figure 5.2: Flow in a DPI: Velocity along the x-direction fields at time t=0.0 s (left) and 1.0 s
(right). The particles are shown with gray color.
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Figure 5.3: Flow in a DPI: axial velocity (y-direction) fields at time t=0.0 s (left) and 1.0 s
(right). The particles are shown with gray color.

As the time progresses, the particles start to move towards the exit section or the top
boundary and eventually exit through the outlet of the inhaler. At time t=1.0s, approximately half
of the particles exited the inhaler.
Figure 5.4 shows the flow fields at time t=0.0s to 6.0s for axial velocity (y-direction) with
different particle diameter than Figure 5.2 and 5.3. The particle movement in fluidized bed can be
seen for different time frame. It shows that the bed was so cohesive at first that no fluidization
occurred at t=0 s and all particles remained in the bed. At t=1 s, the agglomerated particle entrained
into the airflow and the bed starts to fluidize. So, very little particle movement is observed at this
time. But due to the cohesivity between particles, particle agglomeration with the flow becomes
higher and more frequent. Therefore, packed particles are started to move faster and try to leave
the domain. When the gas velocity exceeds the particle’s terminal velocity, then the particle carried
out of a bed at t=6 s. At this time half of the particle leave the inhaler.
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Figure 5.4: Particle movement as a sequence of particle agglomeration with time in a dry particle
inhaler. The particles are shown with red color.
5.2: Effect of Particles Diameter
Particle size plays an important role in determining the possibility of aerosol
particles in the lung. The particle residence time is dependent on the particle size, density, and
fluidization velocity. For a given particle size and composition, this particle residence time usually
larger than the total reaction time. Figure 5.5 and 5.6 depict the change of flow field’s time with
the change of particle size at a constant velocity. The particle movement in fluidized bed can be
seen for different time frame, while the same fluidization velocity has been used in both cases.
With the change of particle size at same fluidization velocity, the smaller particles leave the domain
at 2 seconds while the larger particles take more time to leave the domain.
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Vinlet =1.32 m/s
DP1=3.17 µm
ρp1 =2344.94 kg/m

3

DP2=34.1 µm
ρp1 =1562.45 kg/m

3

Figure 5.5: Flow in a DPI: axial velocity (y-direction) fields at time t=0.0 s (left) and 2.0 s
(right). The particles are shown with gray color

Vinlet =1.32 m/s
DP1=3.89µm
ρp1 =2867.71 kg/m

3

DP2=46.3 µm
ρp1 =1489.88 kg/m

3

Figure 5.6: Flow in a DPI: axial velocity (y-direction) fields at time t=0.0 s (left) and 3.0 s
(right). The particles are shown with gray color.
It is known that particles larger than 6 μm can pass the mucociliary clearance (MCC) in
the ciliated region of the lung [108] and particles with diameters between 1 and 5 μm are preferably
are suitable for inhalation and can reach upto alveolar macrophages in the alveoli [109]. But due
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to the high surface free energy in smaller drug particles, they tend to stick together via cohesive
forces or to any surface they run into via adhesive forces, show poor flowability and aerosolization
performance and have an inclination to remain within the inhaler. To overcome these problems,
carrier particles are used to improve the flowability of drug particles and increase the dispersion
of drug particles during release by diluting the drug to improve accurate dose delivery. In this
regard, several simulations have been run with a wide variation of drug and carrier particle size
distribution to predict the optimal particle movement. After getting a wide range of data for various
particle size distribution, a few are selected for analysis which is shown in Table 5.2. The main
objective of this research is to obtain reproducible, high pulmonary deposition that can be highly
provoked by physico-chemical characteristics of carrier.
Table 5.2: Particle residence time with change of drug particle and carrier particle size (Based on
simulations running on MFiX)
Drug Particle Diameter, µm Carrier Particle Diameter, µm Residence Time,
s
1.80
7.10
4
1.80
7.20
4
1.92
5.13
2
2.40
5.10
4
2.90
6.30
5
3.10
5.10
4
3.11
5.60
3
3.30
6.30
4
3.33
6.30
5
3.40
4.10
4
3.50
5.40
5
3.50
6.10
6
3.66
4.73
3
4.50
6.30
6
5.14
6.37
8
In this project, simulations have been done for different parameter. A particle size
distribution is one of the parameters. This function should be included to accomplish optimal
particle movement by controlling both the particle reaction time and residence time in the fluidized
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bed environment. In this project, drug particles diameter starts from 1.8 to 5.14 µm and carrier
particle diameter from 41 to 72 µm has been chosen based on previous research. So, this table is
created from the data of lowest particle size to highest particle size and several simulations have
been done with a wide variation of drug and carrier particle size range to observe which one shows
better particle movement based on time. In first case, lowest drug particle size is used with highest
carrier particle size and shows residence time of 4 seconds. But in 2nd case, same size of drug
particle mixed with higher size of carrier particle than 1st case and shows comparatively higher
residence time. Then 1.92 µm size of drug particle and 51.3µm of carrier particle only takes 2
seconds time to leave the fluidized domain and can react rapidly into target areas after inhalation.
Also, 3.11 µm diameter drug particle and 5.6 µm carrier shows better residence time which means
they can deliver the medication within a short time. In this study, larger carriers (90–125 µm)
showed a higher drug dispersion than the same formulation with 38–60 µm carriers.
Based on all of the data from Table 5.2, Figure 5.7 is showing the particle movement
timeframe based on particles size changes. From Figure 5.7, it can be seen that with the change of
particle size, the particle residence time has been changed, which changes the time of medicine
delivery into lungs. Smaller size of drug particle is chosen here, so they can reach deeper areas
into the lung but their stronger adhesion to surfaces resulting in a greater loss of particles in the
aerosol and also in the mouthpiece during inhalation. And larger carrier particles have larger
surface discontinuities which gives cover to drug particles from the press-on forces during mixing
[110]. For this reason, lowest size of drug and highest size of carrier particles have been chosen in
2nd case, though better results can be seen from other particle size distribution. Case #3 and #7
show the enhanced inhalation performance among all cases. Increasing size of drug and carrier
particle reduces the inhaler performance by taking the higher residence time (in last case).
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Figure 5.7: Particle Residence time with the change of carrier particle and drug particle size

As particles of 7.5 µm and larger mostly deposit in the oropharynx, whereas particles
smaller than 0.5 µm may be exhaled again, so it is important to select ideal particle size that can
deliver medicine into the respiratory tract with minimal time and act instantly. So it can be
concluded that, drug particles of 1-3.66 µm show a higher drug dispersion and better aerosolization
behavior with carrier particles between 51-63 µm.
5.3: Effect of inlet velocity change
Figure 5.8 depicts the change of flow field’s time at a constant particle size with the change
of velocity. Based on previous analysis, drug and carrier particle size is selected which have better
aerosolization and higher drug dispersion rate. Two different fluid velocity has been chosen to see
particle movement difference throughout the inhaler. The particle movement in fluidized bed can

50

be seen for different time frame with same particle size, while the different fluidization velocity
has been used in both cases. With the change of fluidization velocity at same particle size, the
particles with higher velocity leave the domain at 2 seconds while the same particles with less
fluidization velocity take more time to leave the domain. This is because aerosol particles at higher
fluidization velocity can better follow changes of air flow direction, thus moves fast. But such
higher fluidization velocity results in more turbulence and eddy formation, which impedes the
particle movement inside domain. So, inlet velocity of 2.5 m/s has been chosen as it shows
reasonable results in terms of particle residence time.

(b)

(a)

Figure 5.8: Flow in a DPI: axial velocity (y-direction) fields for (a) at time t=0.0 s (left) and 3.0 s
(right) at Vinlet=2.64 m/s and for (b) at time t=0.0 s (left) and 2.0 s (right) at Vinlet =5 m/s. The
particles are shown with gray color.

As particle velocity influences the lung deposition, so the velocity at which the particle
leaves the inhaler is very important. Consequently, selection of fluidization velocity is an important
parameter in this project. It can been considered that particles (D (v, 2.5) of 3 µm), exhibit superior
properties for leaving the inhaler.
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5.4: Effects of Drug Particle on Lung Delivery:
After inhalation through DPI, the particle enters the respiratory tract and may deposited in different
regions of the respiratory tract. Larger particles (>5 μm) could not follow the air streamline, so
may deposit in these regions by impaction. In fact, deposition by impaction in the oropharyngeal
region remains a major portion of the emitted dose for DPI devices. Contrariwise, small particles
(<0.2 μm) can deposited in all regions of the respiratory tract by diffusion. Sedimentation is the
major deposition mechanism in the small airways and alveolar region for inhaled particles. The
effects of slip, shape and density on aerosol particle behavior is very important for delivering
medications to the peripheral regions of the lungs. Slip correction factors for particles smaller than
10 microns, can derived by Cunningham are as followed:
𝐴3

𝐶𝑐 = 1 + 𝐾𝑛 [𝐴1 + 𝐴2 𝑒𝑥𝑝 (− 𝐾𝑛)]

(5.1)

where, Kn is the Knudsen Number, and A1, A2 and A3 are constants. The values of these
constants were determined in 1945 by Davies [109], and are given by Reist [110] and Hinds [111]
as A1=1.257, A2=0.4 and A3=1.1.
Table 5.3 shows the change of Stokes number for a unit density sphere of a given particle
size using slip correction with the constants. All values are calculated for atmospheric pressure.
Particle settling velocity is also related to the slip correction factors. From Table 5.3, it can be seen
that with the increase of particle diameter the drag forces decreases. Slip correction is significant
for deposition of pharmaceutical aerosol particles. Particle deposition in lungs are dependent of
particle size. Cunningham Slip Correction Factor is used to describe non-continuum effects for
drag calculations on small particles. Without these correction factors, calculation of particle
properties and deposition prospects would be inaccurate.
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Table 5.3: Effect of Cunningham Slip Correction Factor on Stokes Drag and Terminal Settling
Velocity (VTS)
Particle Diameter, µm

Cc

1.80
1.92
2.37
2.89
3.04
3.10
3.11
3.33
3.41
3.45
3.49
3.50
3.66
4.50
5.14

1.092180009
1.086418753
1.070010127
1.057413149
1.054580263
1.053523871
1.053351768
1.049827027
1.048658065
1.048093913
1.047542693
1.047406857
1.045334426
1.036872000
1.032280934

VTS (with Cc)
m/s
1.42E-04
1.93E-04
2.12E-04
3.97E-04
6.06E-04
7.23E-04
4.56E-04
3.99E-04
5.74E-04
5.57E-04
5.85E-04
7.21E-04
6.91E-04
7.42E-04
1.38E-03

VTS(without Cc)
m/s
1.30E-04
1.77E-04
1.98E-04
3.75E-04
5.75E-04
6.86E-04
4.33E-04
3.80E-04
5.47E-04
5.32E-04
5.58E-04
6.88E-04
6.61E-04
7.16E-04
1.33E-03

It can be said from the above table that particle deposition mechanism that have Brownian
motion effects have shown low deposition efficiency for particles with the decreased slip
correction value. For increment of particle size from 1.8 to 5.14 μm, drag force decreases thus
terminal settling velocity increases when a slip correction factor is utilized. Smaller particles settle
more quickly because of their smaller surface area cause less frictional drag force. For particles <5
micron, it is very important to correct for slip when calculating the settling velocity of these size
of particles. When a slip correction factor is applied, then anticipated particle settling velocity
increases. Since submicron particles are used here, so no drastic differences are visible between
the corrected and uncorrected velocity values.
Figure 5.9 shows the difference of slip correction factor on particle diameter. Smaller size
of drug particle have higher slip correction, which means these micron size particle has include
effects of Brownian motion thus results in low deposition efficiency in the upper airways. The
53

resultant slip correction factor here is greater than unity and decrease linearly with particle
size. When the particle size is 1.8 micron, then the slip correction factor is 1.092. With the
increased particle size, the slip correction factor decreases and particle shows higher deposition
efficiency in the upper airways. For this micron size particles, diffusion is always the dominating
deposition mechanism. If diffusion coefficient is only due to diffusion, it is independent of particle
density, because the diffusivity of particles is independent of particle mass.

Particle Diameter Vs slip correction factor Cc
1.1
1.09
1.08

Cc

1.07
1.06
1.05
1.04
1.03
1.02
1.5E-06

2.0E-06

2.5E-06

3.0E-06

3.5E-06

4.0E-06

4.5E-06

5.0E-06

5.5E-06

Particle Diameter, m

Figure 5.9: Difference of slip correction factor on particle diameter
Particles usually deposited due to inertial impaction and sedimentation. Particle deposition
is directly dependent upon the relaxation time of the aerosol particle. Relaxation time describes
the time required for a particle to adjust its velocity to a new state of forces. It indicates the
particle's ability to acclimate quickly to a new condition. It depends on the mass and movement of
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the particle, and is not influenced by the external forces acting on the particle [112]. Particle
relaxation time can be expressed with following equations:
𝜏=

𝑑𝑝 2 𝜌𝑝
18𝜇

(5.2)

𝐶𝑐

where, dp is particle diameter, ρp is particle density, 𝜇 is air viscosity and Cc is Cunningham Slip
Correction Factor.
Particle Diameter Vs Relaxation Time
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Figure 5.10: Relationship between particle relaxation time with the change of particle diameter
Figure 5.10 shows the relationship between particle relaxation time with particle diameter.
The dimensionless relaxation time is usually used to understand the particle deposition in a fluid
flow field. As relaxation time is proportional to the square of particle diameter, it increases rapidly
with the increase of particle size. From the figure it is seen that, small particles have shorter
relaxation time as they need less time to adjust to the fluid flow well. Smallest particle 1.8 μm took
(14 μs) very short time to react with other particles and adjust into fluid flow. As particles become
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larger in size, they tend to stick more to their primary track and took more time to react with other
particles and adjust to flow field. So, it can be concluded that choice of smaller particle will be
best for particle deposition in lungs.

5.5: EFFECTS OF PARTICLE SIZE DISTRIBUTION ON RESPIRATORY TRACK:
It is known from the previous studies that, larger particles between 10–15 µm deposit
mostly in the upper airways while particles between 5–10 µm can reach the large bronchi, and
particles of 1–5 µm penetrate to the lower airways and lung periphery [113]. So, it is important to
define a desired particle size for better inhalation through inhaler device that can deliver the
medications into targeted areas. For clinical use, inhaler devices can deliver polydisperse particle
sizes i.e., mix of sizes in the aerosol particles. On the other hand, monodisperse aerosols consist
of a single particle size, which are rare in nature and medicine.
A measure that calculates a polydisperse aerosol is the mass median diameter (MMD). This
measure determines the particle size (in µm) above and below which 50% of the mass of the
particles is surrounded [114]. This is the particle size that evenly divides the mass, or amount of
the drug in the particle size distribution. The higher the MMD, the more particle sizes are of larger
diameters.
The mass median diameter (mmd) is the most commonly used parameter for drugs
inhalation in DPI device. The mass median diameter (mmd: the diameter above which 50% of the
aerosol mass is contained) is a good parameter to define in this project, though the size fraction for
which mmd is calculated should be defined also. Inhaled aerosols are usually defined by lognormal
size distributions that are described by a mass median diameter (MMD) and geometric standard
deviation (GSD) [115]. While these parameters generate statistics on relative proportions of
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particle sizes, which mass distribution is more important, precisely describe the percentage of total
mass from particles in the submicron range. Table 5.4 shows the particle size distribution defined
by a mass median diameter (MMD).
Table 5.4: Particle size distribution defined by a mass median diameter (MMD)
Particle
Diameter,
µm
1.80

Density
,ρ
(kg/m3)
1333.76

Mass, Mi

MiDi

N

NiDi

4.07282E-15

7.33E-21

500

1.92

1596.94

5.91823E-15

1.14E-20

500

2.37

1170.09

8.15575E-15

1.93E-20

500

2.89

1491.32

1.88479E-14

5.45E-20

500

3.04

2065.09

3.0378E-14

9.23E-20

500

3.10

2372.08

3.70011E-14

1.15E-19

500

3.11

1485.85

2.34022E-14

7.28E-20

500

3.41

1562.41

3.24383E-14

1.11E-19

500

3.33

1136.94

2.19821E-14

7.32E-20

500

3.45

1483.5

3.18966E-14

1.10E-19

500

3.49

1521.99

3.38757E-14

1.18E-19

500

3.50

1866.24

4.18959E-14

1.47E-19

500

3.66

1639.36

4.2084E-14

1.54E-19

500

4.50

1173.52

5.59922E-14

2.52E-19

500

5.14

1677.66

1.19287E-13

6.13E-19

500

Σ=5.11301E- 1.96E-18
13

8000

9.00E04
9.60E04
1.19E03
1.45E03
1.52E03
1.55E03
1.56E03
1.71E03
1.67E03
1.73E03
1.75E03
1.75E03
1.83E03
2.25E03
2.57E03
2.53E02
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NMD, MMD,
µm
µm
3.16

3.83

GSD
1.368

All the calculations have been done based on previous data from this project. These
findings will be beneficial to better understand the effect of micronized drug particle size into
respiratory deposition. For a fixed MMD, the particle size range is greatly affected by the GSD.
Mass of spherical particle is calculated by 𝑀 =

𝜋𝑑3 𝜌𝑝 𝑁
6

, where N is the number of particle. For

these selected particle size the mass median diameter is 3.83 µm. It means that particle with
diameter of 3.83 µm evenly divides the mass, or amount of the particle in the particle size
distribution. The higher the MMD, the more particle sizes are of larger diameters. For MMD of
3.83 µm, the GSD got is 1.368, the number median diameter (NMD) is 3.16 µm which is still into
the submicron range, assuring that more than half of the particles are submicron in size. For particle
size of 1.8 µm, the aerodynamic diameter is .66 µm. And for the highest drug particle size of 5.14
µm, the aerodynamic particle diameter is 0.044 µm. So, the aerodynamic diameter of all the
particles are around 0.5 μm, which means they have the highest probability of depositing in the
lung and the smaller sizes have greater probability to penetrate into the deep lung [116]. The larger
the GSD value, the greater the spread of the aerodynamic diameters of the residual particles. So,
for particles with relatively small MMDs (around 1-4 um), submicron particles considerably
interject to pharmaceutical effect, but as MMAD increases, this effect is decreased.

5.6: Fluid Flow Visualization Inside DPI:
To study the air flow through the device a numerical simulation has been conducted by
ANYS FLUENT. The geometry and standard settings kept same with MFiX simulations and
222111 rectangular cells was created to get a smooth visualization. The simulation was performed
using discrete phase model for particle tracking. For better understanding the fluid flow inside the
inhaler domain, contour and vector fields are important.
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Figure 5.11 shows the velocity contour of fluid flow inside the computational domain. The
air flow achieved a velocity of approximately 2.15 m/s when leaving the inlet and entering the
inhaler domain. Particles are introduced into the domain with a very small velocity, which is
negligible and cannot influence the fluid flow behavior anymore inside the domain. Due to no slip
boundary conditions at wall surface, a minor velocity fluctuations is visible on both side of inhaler.
But it stabilizes quickly with the flow. So, constant fluid velocity is observed throughout the
domain.

Figure 5.11: Velocity contour of air flow inside the computational domain
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Figure 5.12 shows the velocity streamline of air flow inside the computational domain.
Streamlines are a set of curves that are directly tangent to the velocity vector of the flow. It defines
the direction that a fluid element travels in at any point in time. From the figure 5.12 it is seen that
all the fluids are moving towards the outlet section. As particle are introduced to the flow field,
few turbulence created in some region and the simulation shows little bit velocity fluctuations A
little bit of flow fluctuation is visible near the inlet and wall regions as the particle velocity meets
the fluid velocity but steadies quickly. But no reverse flow is observed through velocity field.
Because of a smooth fluid flow with no backward flow inside the domain, all the particles can
easily escape through the outlet.

Figure 5.12: Velocity streamline of air flow inside the computational domain
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Figure 5.13 shows the velocity streamline of particle inside the computational domain. All
particle are introduced through the bottom inlet section. When particles mix with the fluid, their
velocity increases in very small magnitude. This velocity fluctuation is small enough in the interior
section, so it does not influence the flow behavior anymore inside the domain. Due to no slip
boundary conditions at wall, particles may reflect into the fluidized bed and show a minor velocity
fluctuations on both side of inhaler, which is negligible. But it stabilizes quickly with the flow.
Because of no turbulence and eddy formation, particles can easily escape through outlet section
on the top. So, a smooth flow behavior can be seen in the rest on domain which is good for efficient
particle movement including escapes to the outlet.

Figure 5.13: Particle velocity streamline inside the computational domain
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5.7: Flow in A 3D Fluidized Bed with MFiX:
A 3D Eulerian-Lagrangian model has been simulated with the MFiX-PIC solver. Fluid is
considered as a continuum while “parcels” represent groups of real particles with analogous
physical characteristics. Figure 5.14 represents the gas velocity on MFiX 3D fluidized bed
simulation from beginning to the end frame. 500 frames have been created during solving the
whole simulation. It can be seen from the above figure that, at the beginning the gas velocity is
constant as we implement to the simulation. As the particle enters the domain the gas velocity
starts to change.

Figure 5.14: Gas velocity on MFiX 3D fluidized bed simulation from the beginning to end
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Particles have their own (very small) velocity which mixes with the gas flow, so slight
changes are visible in gas flow. Parcels movement is easily visible through the outlet section. Since
the outlet section is constricted, so when the parcels exit the velocity becomes higher to that
section. But overall, a slight variation is visible in gas velocity on 3D computational domain which
is good for parcel movements.
Figure 5.15 depicts the fluid velocity in z-direction for 3D fluidized bed simulation. No
significant changes can be seen through the fluid velocity in z direction. When the particles exit
the outlet section, due to the constricted outlet section, high particle concentration occurs on that
region. So, velocity changes in z-direction can be visible on outlet region. The lowest fluid velocity
in z-direction is found at the outlet section. The velocity in z- direction decreases along with the
height. The velocity is higher and it is almost constant near the bottom. This parameter can only
be used in 3D cases to observe the flow field.

Figure 5.15: Velocity in z-direction on MFiX 3D fluidized bed simulation
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Void fraction is an important parameter to define the gas-solid phase, denoted by εg for the
fluid phase. This variable represents the amount of empty space between particles at each
condition. Figure 5.16 depicts the void Fraction on MFiX 3D fluidized bed simulation. At the first

(b)

(c)
Figure 5.16: Void Fraction on MFiX
3D fluidized bed(d)simulation

frame, no particle is present in the domain. So, the void fraction is magnitude of 1. As the particles
introduced, the contours show low values of void fraction near inlet section. Due to parcle
movement the void fraction decrease. As varying particle diameter is used in this 3D simulation,
so with the parcel movemet the void fractions are changing. Therefore the void profiles are
different with time frame.. The voidage profiles near the inlet section are identical showing a high
(e)

(f)
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(h)

value near the bottom and low value near the top on figure 5.16(d). When all the parcel leave the
domain, the void fraction in the domain becomes 1 again in figure 5.16(h). This fraction are used
to analyze the gas-solid mixing and process efficiency.
Figure 5.17 shows the pressure field on MFiX 3D fluidized bed simulation. On figure
5.16(a), whole 3D domain with particles can be seen for pressure field. Red color represents carrier
particles where blue ones are the drug particles. Particles are leaving through the outlet section on
the left figure. Based on the real case scenarios, the pressure for the whole domain was chosen
and it is ideal to maintain the whole domain at that constant pressure. No significant pressure
change is observed on the computational domain. Better visualization of pressure field can be
visible on figure 5.17(b).

Figure 5.17: Pressure field on MFiX 3D fluidized bed simulation
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5.8: Data Analysis for 3D Simulation:
An important parameter for data analysis is determining the key variables as an output
parameter using Sampling method. This method creates sets of samples according to the
probability distributions of the uncertain variables and sets them into corresponding sets of
response functions, where the number of samples is specified by the samples integer specification
[117]. Means, standard deviations and 95% confidence intervals are calculated for the response
functions.
Table 5.5: Mean and Standard Deviation (SD) values of variables used in the 3D case. All the
units are in the SI system.
Variable name
Description of the variable
Mean value
SD
V1

velocity of air

1.5

0.4

V2

viscosity of air

1.8E-05

3.6E-06

V3

drug particle diameter

5.3E-05

1.1E-05

V4

drug particle density

2650

530

V5

carrier particle diameter

3.2E-06

6.4E-07

V6

carrier particle density

1520

304

V7

normal coefficient of restitution for 0.5
parcel-wall collisions
drag correlation
6

0.16

0.5

0.166

3

0.66

0.5

0.166

V12

tangential coefficient of restitution for
parcel-wall collisions
volume fraction exponential scale factor
in frictional stress model
the empirical dampening factor for the
frictional stress model,
solids slip velocity scale factor

0.5

0.166

V13

density of air

1.205

0.241

V14

the pressure at the top boundary

1atm - 4000

800

V8
V9
V10
V11
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Ten different drag models considered in this study are GIDASPOW_BLEND_PCF, BVK,
GIDASPOW,

GIDASPOW_BLEND,

GIDASPOW_PCF,

SYAM_OBRIEN,

WEN_YU,

WEN_YU_PCF, KOCH_HILL, and KOCH_HILL_PCF. Correlation coefficients are important to
determine which variables play most vital rules in calculations and show the strength of effects of
each parameters. Therefore, instead of focusing on lots of variables it’ll be easy to determine the
most effective parameter that can dominate the simulation. Correlations are calculated between
two sets of sample data. So, the calculation of correlation coefficients can be done between two
input variables, between an input and an output variable or between two output variables. The
simple correlation coefficients is defined for two variables x and y as: Corr(x; y)=
̅̅̅̅)
∑𝑖(𝑥𝑖 −𝑥̅ )(𝑦𝑖 −𝑦
√∑𝑖 (𝑥𝑖 −𝑥̅ )2 ∑𝑖(𝑦𝑖 −𝑦̅)2

. Correlation coefficient varies from 0 to 1. If the value is close to 0, then the

variable is negligible and has less effects on simulations.
Table 5.6: Partial Correlation Matrix between input variables and residence time
Input Variable
V1
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13
V14

Input Correlation coefficient with residence time
-9.91E-01
-8.41E-02
-5.52E-02
2.88E-01
2.77E-01
4.53E-01
1.11E-01
4.32E-01
-5.96E-01
7.20E-01
-4.23E-01
-6.99E-02
-3.17E-01
-1.23E-02
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Table 5.6 shows correlation coefficients between input variables and residence time. It is
seen from the table that air velocity, carrier particle diameter, density and volume fraction plays
most dominant role in this 3D DPI simulation. The values close to 1 have more effects on
simulation, while values nearly 0 have negligible effects. Solid slip velocity factor and air viscosity
effects has minimal effects on this 3D analysis.
In the present study, the data generated with Dakota-MFiX for 500 samples are used for
the data-driven framework and 50 points are used for testing. Deep neural network algorithm is
used in TensorFlow to predict the mean quantities of interest. The predicted mean QOIs are
forwarded to DAKOTA via the C++ wrapper to get the statistics for residence time. The neural
network is consists of two hidden layers and one input as well as the output layer. An adaptive
gradient-based optimization method is used to lessen the cost function in the neural network. The
predicted values from the algorithm are compared with the actual values for the test dataset. In
statistics, the actual value is obtained by measuring the available data and the predicted value is
the value of the variable predicted based on the regression analysis.

Figure 5.18: Comparison of actual residence time and predicted residence time for 50 cases
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Figure 5.18 shows the cumulative probability for the mean quantities of interest in terms
of residence time. The predicted residence time from the algorithm for the test dataset are
compared with the actual values. Residuals are graphically symbolized by means of a residual plot.
When the difference between these values are positive, then the data points are above the
regression line and if the difference is negative then the data points are below the regression line.
Difference between the actual value and the predicted value is called residual. The residuals play
an important role to validate the regression model. On above figure, few of the points are near
regression line indicate positive residual values. Most data points lie on the regression line
indicates that the difference is zero. As most of the predicted values are close to the actual values
in the plot that means it follows linear regression and have a good fit. Most of the predicted values
are the same as the computed values over the range of 1-1.65 on Figure 5.18 means that the model
can provide an adequate fit and does not need to revise. The mean square and variance for the
predicted and actual values are 0.02 and 0.94, respectively.

Usually, uncertainty quantification (UQ) is used to advance the understanding of how
variations in the parameters affect the response functions of any computational applications. In
this project, UQ is performed by calculating approximate response function distribution statistics
based on specified input random variable probability distributions [118]. These response statistics
contain response mean, response standard deviation, skewness and kurtosis values. In this study,
the data generated with Dakota-MFiX for the sample size of 500 is used for the data-driven
framework. The mean and standard deviation of the response function is 1.5386 and 0.533868
respectively.
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A deep neural network algorithm is used in the TensorFlow library to attain reliable
statistics of mean quantities of interest. The data collected from Dakota-MFiX simulations is used
to train as well as validate the machine learning algorithm. The validated algorithm is used to
predict mean quantities of interest. The predicted functions are passed to Dakota via the C++
wrapper to obtain statistics of the residence time across the fluidized bed with LHS method based
on 500 samples for 14 uncertain input parameters with various distributions. Sampling method
shows sets of samples according to the probability distributions of the uncertain variables and maps
them into corresponding sets of response functions, when the number of samples is known [117].
Table 5.7: Low order statistics of QoIs for different sample sizes
Samples
QoI Mean
QoI SD
1000
1.7152
0.6024
10000
1.6844
0.5802
100000
1.3022
0.5062
200000
1.1252
0.4858
Means, standard deviations and 95% confidence intervals are computed for the response
functions. Based on 95% confidence intervals for response function, the LowerCI_Mean,
UpperCI_Mean,

LowerCI_StdDev

and

UpperCI_StdDev

are

1.4917280142e+00,

1.5855450360e+00, 5.0270266567e-01 and 5.6918428097e-01 respectively. With 95%
confidence the actual value of each parameter falls between the intervals specified and assume the
misfit between the model and corresponding data. The effect of sample size on the QoIs has been
studied in this project. The mean value decreases with an increase in the sample size. A similar
trend in standard deviation is visible on Table 5.7. It is observed that approximately 100000
samples provide reliable intervals for the QoIs.
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5.9: Summary
This study shows the development of a novel high fidelity CFD-DEM method and
sensitivity analysis for predicting the transport and deposition of for DPI carrier and API particles
with agglomeration and deagglomeration. Current work shows the range of validity for using
simulations based on a 2D Cartesian coordinate system to assess a rectangular fluidized bed with
different parameter. The simulations has been conducted for different inlet gas velocities with
different particle diameter, which correspond to the bubbling and slugging regimes of fluidized
beds. Current analysis shows that drug particles of 1-3.66 µm show a higher drug dispersion and
better aerosolization behavior with carrier particles between 51-63 µm on basis of residence time.
A 3D simulation has been done for large amount of particles using MFiX-PIC model to acquire
actual DPI performances. In this study, the data generated with Dakota-MFiX for the sample size
of 500 is used for the data-driven framework. The mean and standard deviation of the response
function is 1.5386 and 0.533868 respectively. Means, standard deviations and 95% confidence
intervals are computed for the response functions. Based on 95% confidence intervals for response
function, the LowerCI_Mean, UpperCI_Mean, LowerCI_StdDev and UpperCI_StdDev are
1.4917280142e+00, 1.5855450360e+00, 5.0270266567e-01 and 5.6918428097e-01 respectively.
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Chapter 6: Conclusion and Future Works

6.1: Project Summary: Recently besides asthma and COPD, other pulmonary diseases such as
cystic fibrosis, lung cancer and pulmonary infectious diseases and also systemic disorders such as
diabetes, cancer, neurobiological disorders are considered to be treated by pulmonary drug
delivery [78]. Due to DPI’s numerous advantages over other pulmonary drug delivery systems,
the inhalation performances are trying to be improved by changing, drug and carrier particle
engineering and formulation strategy. This research has provided the understanding of aerosol
particle behavior within DPI device by identifying the mechanisms and the factors that have the
most influence on inhaler behavior. It has shown that this behavior can be portrayed
computationally using a CFD-DEM technique and can use DEM a viable tool in the design and
virtual testing of new DPI designs. The main objective in this research is to obtain reproducible,
high pulmonary deposition by successful particle selection and careful process optimization.
This study shows the development of a novel high fidelity CFD-DEM method and
sensitivity analysis for predicting the transport and deposition of for DPI carrier and API particles
with agglomeration and deagglomeration [119-121]. Since DPI particle transport is affected by
particle-particle interactions, heterogeneous particles sizes and shapes, electrostatic and Van der
Waals forces, they show considerable challenges to CFD modelers to model regional lung
deposition from a DPI. The combination of computational modeling and sensitivity analysis was
used magnificently to validate the models with available data from the literature for DPI for various
formulation properties and their effects on particle size distribution with DAKOTA. The
uncertainty quantification results with MFiX-DAKOTA framework for the fluidized bed with
central jet having uncertain input variables. The average bed height decreases with the decrease in
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standard deviation of the input variables that shows good agreement with the results from previous
work done with MFiX-PSUADE framework.
For attaining the objectives of the project, this present work shows the range of validity for
using simulations based on a 2D Cartesian coordinate system to assess a rectangular fluidized bed
with different parameter. The simulations has been conducted for different inlet gas velocities with
different particle diameter, which correspond to the bubbling and slugging regimes of fluidized
beds. After all these analyses, a novel high fidelity discrete element (CFD-DEM) method and
sensitivity analysis is developed for predicting the transport and deposition of carrier and API
particles. Ideal particle size is determined based on residence time for better DPI performances
and respiratory deposition. Current analysis shows that drug particles of 1-3.66 µm show a higher
drug dispersion and better aerosolization behavior with carrier particles between 51-63 µm on
basis of residence time. ANSYS FLUENT simulation shows the visualization of fluid and particle
flow inside inhaler domain. To acquire real-world DPI performances, a 3D simulation has been
done for large amount of particles using MFiX-PIC model which needs to be developed for further
analysis. Table 6.1 shows the parameters obtained from present CFD-DEM analysis that can be
used for scrutinizing DPI devices performances.
Table 6.1: Anticipated parameter for better DPI performances (based on CFD-DEM method)
Parameter
Drug particle
Carrier particle
Desired inlet velocity
Particle velocity
Pressure drop

Value
1-3.7
51-63
2.5
0.01
4000

Unit
µm
µm
m/s
m/s
Pa

For 3D fluidized bed, a deep neural network algorithm is used in the TensorFlow library
to attain reliable statistics of mean quantities of interest. The data collected from Dakota-MFiX
simulations is used to instruct and validate the machine learning algorithm. The validated
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algorithm is used to predict mean quantities of interest. The predicted functions are passed to
Dakota via the C++ wrapper to obtain statistics of the residence time across the fluidized bed with
sampling method based on 500 samples for 14 uncertain input parameters with various
distributions. While four input parameters show more influence, the remaining ten input
parameter’s influence on mean quantities of interest is negligible. However, these observations are
in good agreement with previous works [68].

6.2: Future Work/Recommendations: Advancements in DPI show a substantial development in
pulmonary delivery technology. While current research identifies ideal types of particle size
distribution, it does not relate these quantitatively to dose fluidization emerging into the lungs.
Current work only focuses on inhaler performances based on particle size distribution and based
on these particle sizes, particle transport and respiratory deposition has been presumed. But further
experimental work is required to quantitatively correlate the exit particle size distribution to the
dose fluidization method. Furthermore, the studies described in this work could be the basis of
future research regarding the relation between particle size distribution and inhaler performances.
The results presented in this research arise new queries about DPI process and a number of methods
for further research are listed below:
 Current work focuses the CFD-DEM method of particle distribution inside DPI device. But
the transport and deposition of this size ranges into respiratory track after leaving inhaler
domain has not been shown computationally, which can be shown for future advancement
of this project.
 Detailed UQ analysis for further 3D MFiX fluidized bed modeling can be added as
continuation of this research [122].
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 Several design modifications needs to be done on modeling the fluidized bed simulations
to develop a novel high fidelity discrete element (CFD-DEM) method. For this purpose,
the following parameters needs to be investigated:


change of fluid property



changes of air pressure



vary with different inhaler geometry

 For enhancing the effectiveness of pulmonary drug formulations, particle shape,
morphology and hygroscopicity will need to develop which have not been discussed in this
research. This approach in future work technologies may enable more drugs to be delivered
through for treatment of lung diseases or systemic therapy.
 A comparative study between all models will be beneficial to explore the uncertainty
quantification.

 Development of a novel high fidelity discrete element (CFD-DEM) method and sensitivity
analysis needs to be carried out using DAKOTA for predicting the transport and deposition
as well as the agglomeration and deagglomeration for DPI carrier and API particles.

 Current work has demonstrated that DEM is capable of capturing particle detailed
information in DPI, but further work is required to illustrate insights into the dose behavior.

 The dose fluidization have not been investigated in this work, but play an important role in
the dose behavior. It depends on several factors like relative humidity, powder preparation
processes etc. So, further experiments are necessary to quantify such effects and also dose
fluidization.
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 The therapeutic efficacy of the inhalation therapy has not been investigated in this project.
It can be computed by using clinical parameters only and suitable subject for further
research.
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Appendix:
α = Thermal diffusivity [m2/s]
λ = Thermal conductivity [W/m.K]
ρ = Density [kg/m3]
ε = Volume fraction
Igm = Momentum between the fluid phase and the mth solid phase
̿Sg = Stress tensor
̿τg = Stress tensor
μg = Dynamic coefficients of viscosity
λg = Second coefficients of viscosity
g = Gravity
Cc = Cunningham slip correlation constant
G = Incident radiation [W/m2]
J = Molecular diffusion flux [mol / (m2-s)]
P = Pressure [Pa]
V = Volumetric flow rate [m3/L]
M = Molecular mass [kg]
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